Market Overview

NeoTract Announces Sponsorship of Fourth Annual Drive For Men's Health

Share:





NeoTract, Inc., a medical device company focused on addressing unmet
needs in the field of urology, announced its sponsorship of the fourth
annual "Drive for Men's Health" event. Funds raised by the Drive for
Men's Health will be donated to Florida Polytechnic University and
Cochrane Urology, a division of Cochrane Collaboration, a global
independent network of researchers, professionals, patients, and
caregivers working to produce credible, accessible health information
that is recognized as the gold standard for trusted research and
information.

Timed to coincide with National Men's Health week, the Drive for Men's
Health is designed to increase awareness of men's health issues and to
encourage men to make their health a priority. During the Drive, Jamin
Brahmbhatt, M.D., and Sijo Parekattil, M.D., co-directors of The PUR
(Personalized Urology & Robotics) Clinic at South Lake Hospital, in
affiliation with Orlando Health, will climb into a blue and white Tesla
Model S and embark on a 3,500 mile cross-country journey beginning in
Florida on June 3 and ending in Utah, via New Orleans, Houston, and Los
Angeles. Throughout the journey, the drivers will make stops that will
feature speakers, events and educational activities to raise awareness
about men's health. The drive will conclude with a 5k run/walk in Salt
Lake City on June 10.

"We are thrilled to support the Drive for Men's Health once again," said
Dave Amerson, president and CEO of NeoTract. "Drs. Brahmbhatt and
Parekattil's commitment to raising awareness about men's health issues
inspires men to take more care with their health. Their efforts help to
dispel myths about urological health conditions and encourage men to see
their doctor. In the case of benign prostatic hyperplasia, or BPH, many
men may assume symptoms are an inevitable part of aging. Education is
the key to getting men to see their doctors sooner and more frequently
to prevent a common problem from becoming more serious."

In 2016, the Drive for Men's Health reached more than 300 million people
through news stories, live appearances on local news, live streaming
from the road, call-in radio shows, and social media in addition to
their scheduled stops. This year, urologists Lance Walsh, M.D., Ph.D.,
Steven Gange, M.D. FACS, and Gregg Eure, M.D., FACS will be talking via
webcast during the Drive about BPH symptoms and the UroLift System as a
minimally invasive treatment option.

"NeoTract is an important and valued sponsor for the Drive for Men's
Health. The UroLift System provides a proven minimally invasive option
for men suffering from enlarged prostate," said Dr. Sijo Parekattil,
urologic surgeon and co-founder of the PUR clinic. "Part of our mission
is to educate men and their partners that there are safe and simple
procedures such as the UroLift System available to them. Our mission is
closely aligned with the work of NeoTract and their involvement enables
us to educate and encourage men to see their doctors."

Nearly 40 million men in the United States are affected by BPH. Not to
be confused with prostate cancer, BPH occurs when the prostate gland
that surrounds the male urethra becomes enlarged with advancing age and
begins to obstruct the urinary system. Symptoms of BPH often include
interrupted sleep and urinary problems, and can cause loss of
productivity, depression and decreased quality of life.

About the UroLift System

The FDA-cleared UroLift System is a proven, minimally invasive
technology for treating lower urinary tract symptoms due to benign
prostatic hyperplasia. The UroLift permanent implants, delivered during
a minimally invasive transurethral outpatient procedure, relieve
prostate obstruction and open the urethra directly without cutting,
heating, or removing prostate tissue. Clinical data from a pivotal
206-patient randomized controlled study showed that patients with
enlarged prostate receiving UroLift implants reported rapid and durable
symptomatic and urinary flow rate improvement without compromising
sexual function. Patients also experienced a significant improvement in
quality of life. Most common adverse events reported include hematuria,
dysuria, micturition urgency, pelvic pain, and urge incontinence. Most
symptoms were mild to moderate in severity and resolved within two to
four weeks after the procedure. The UroLift System is available in the
U.S., Europe, Australia, Canada, Mexico and South Korea. Learn more at www.UroLift.com.

About NeoTract

NeoTract, Inc. is dedicated to developing innovative, minimally invasive
and clinically effective devices that address unmet needs in the field
of urology. The company's initial focus is on improving the standard of
care for patients with BPH using the UroLift System, a minimally
invasive permanent implant system that treats symptoms while preserving
normal sexual function. Learn more at www.NeoTract.com.

View Comments and Join the Discussion!
 

Partner Center